Icrucumab  (Synonyms: Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1)

Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

VEGFR1/FLT1

Icrucumab (30 μg/mL) attenuates Dexamethasone (HY-14648)-mediated conversion of M1 macrophages to an M2-like phenotype by inhibiting FLT-1 (VEGFR-1), increases the expression of M1 markers and decreases the expression of M2 markers, thereby regulating the polarization of tumor-associated macrophages and indirectly affecting tumor progression^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2321  [NCBI]

P17948

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.68 kDa

1024603-92-6

Liquid

Colorless to light yellow

[Icrucumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized VEGFR-1 Protein, Human (328a.a, HEK293, His, HY-P73065) can bind Icrucumab. The EC₅₀ for this effect is 5.461 ng/mL.
• 
  Flow cytometric analysis of 1X10⁶ HUVEC cells with Icrucumab (HY-P99364, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. LoRusso PM, et al. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014;32(2):303-311.  [Content Brief]

  [2]. Shamekh M M, et al. Dexamethasone drives macrophage repolarization linked to increased triple-negative breast cancer aggressiveness[J]. Cell Death & Disease, 2025.

  [3]. Shtam T A, et al. Assessment of inhibition of the growth of breast and colon tumors when blocking VEGFR-1 with monoclonal antibodies[J]. Nanobiotechnology Reports, 2024, 19(2): 291-298.